This is crucial as secreted sema3G is a potential biomarker for evaluating disease stage and its downstream factors, neuropilin-2/PlexinA4 receptor and Rac1, may also represent therapeutic targets in ALS/FTD treatment. This evidence concerns the gene SEMA3G and frontotemporal dementia.